Under New Clinical Development Paradigm, Evidence Development Is Essential To Product Success
This article was originally published in The Gray Sheet
Executive Summary
Former CMS official Sean Tunis advised device manufacturers to demonstrate better effectiveness and value of new medical devices in their clinical trial development under a new clinical development paradigm.
You may also be interested in...
FDA Validates Tool For Incorporating Patient Preferences In Regulatory Decisions
A pilot study that explored how much risk patients would be willing to tolerate from a device implant in order to achieve significant weight loss is helping CDRH regulators understand how to accurately and reliably measure patient preferences. The goal is to start incorporating those preferences into regulatory decisions for certain devices, officials explained at a Sept. 18-19 workshop.
News Briefs: Health Care Spending; Boston Sci In Shanghai; New Products
CMS releases health care spending estimates. Boston Scientific opens new centers in Shanghai. New products from Crosstrees, Biotronik and JenaValve.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.